司帕沙星治疗无合并症淋病疗效观察

Clinical efficacy of sparfloxacin in the treatment of noncomplicated gonorrhea

目的 :探讨司帕沙星治疗无合并症淋病的应用前景。方法 :自 1998年 6月至 1999年 9月对涂片法确认的无合并症淋病患者治疗组 6 6例 ,口服司帕沙星 40 0 mg,每晚治疗 ,疗程 3d;对照组 6 0例 ,头孢曲松1.0 g一次肌注。结果 :司帕沙星对无合并症淋病治愈率为 89.4% ,头孢曲松对无合并症淋病治愈率 96 .7% ,两者间差异无显著性。结论 :司帕沙星作为口服制剂 ,治疗无合并症淋病安全、有效、方便。

Objective: To study the clinical efficacy of sparfloxacin in treating of noncomplicated gonorrhea. Method: Sufferers of noncomplicated gonorrhea who were diagnosed by smear between Jane of 1998 and September of 1999 were treated by sparfloxacin and ceftriaxone. Sparfloxacin group ( n =66): 400mg, oral doses, qn for three days, ceftriaxong group ( n =60): 1.0g, once time intramuscular injecton. Result: The cure rate of sparfloxacin′s group is 89.4%, and that of ceftriaxone′s group is 96.7%. There were no statistically significant differences. Conclusion: Oral sparfloxacin is a safe, efficient and convenient antibiotic in treating noncomplicated gonorrhea.